Madrigal Q3 Rezdiffra sales jump on strong demand, posts first profit

What happened

Madrigal Pharmaceuticals reported third-quarter Rezdiffra sales rose 50% year over year and posted its first profitable quarter. The company nearly doubled its Rezdiffra patient count from the third quarter of 2025 as prescriber adoption deepened.

Confirmed

Global impact / market context

Reaching a first profit means Madrigal now keeps money after paying its costs, reducing reliance on outside funding. Lower research spending helped, while a larger patient base suggests doctors are prescribing more, which supports future revenue growth.

Analyst inference

Analysts on average rate the stock a buy, split into 19 buy ratings, one hold and no sells, with a median 12-month price target of $670. This suggests most analysts expect the improved sales and profit trend to continue, though targets are not guarantees.

Analyst inference

What to watch

1. Madrigal expects the U.S. F2-F3 MASH market it targets to grow more than 30% by the end of 2026, which means a larger group of treatable patients. Confirmed
2. The company plans to start a Phase 3 trial called MAESTRO-CSPH for F4c MASH in the first half of 2027, which means a later-stage test in people. Proposed
3. Results from the MAESTRO-NASH OUTCOMES trial are expected in late 2027. Success could expand the treatable patient group, while failure could limit future sales growth. Analyst inference

Evidence

• Original source link unavailable